| Cas No.: | 906673-24-3 |
| Chemical Name: | Crisaborole |
| Synonyms: | 4-((1-Hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-5-yl)oxy)benzonitrile;AN-2728;4-((1-Hydroxy-1,3-dihydrobenzo-[c][1,2]oxaborol-5-yl)oxy)benzonitrile;4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]Benzonitrile;5-(4-CYANOPHENOXY)-2,3-DIHYDRO-1-HYDROXY-2,1-BENZOXABOROLE;AN 2728;Crisaborole;5-(4-Cyanophenoxy)-1,3-dihydro-1-hydroxy-[2,1]-benzoxaborole;AN2728;Eucrisa;Crisaborole topical ointment 2%;Crisaborole (AN2728);Q2R47HGR7P;AK102641;4-[(1-hydroxy-3H-2,1-benzoxaborol-5-yl)oxy]benzonitrile;4-[(1-hydroxy-1,3-dihydr;4-[(1-hydroxy-1,3-dihydro-2,1-benzoxaborol-5- |
| SMILES: | O1B(C2C([H])=C([H])C(=C([H])C=2C1([H])[H])OC1C([H])=C([H])C(C#N)=C([H])C=1[H])O[H] |
| Formula: | C14H10BNO3 |
| M.Wt: | 251.0451 |
| Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: | AN-2728 is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines. AN-2728 appears to have good therapeutic potential, although further and larger trials are required to assess the long-term safety and characterize the broad utility of this drug. AN-2728 shows potent activity both in vitro and in vivo. AN-2728 is now in clinical development for the topical treatment of psoriasis and being pursued for the topical treatment of atopic dermatitis.For the detailed information of AN-2728, the solubility of AN-2728 in water, the solubility of AN-2728 in DMSO, the solubility of AN-2728 in PBS buffer, the animal experiment (test) of AN-2728, the cell expriment (test) of AN-2728, the in vivo, in vitro and clinical trial test of AN-2728, the EC50, IC50,and affinity,of AN-2728, Please contact DC Chemicals. |
MSDS
COA
| LOT NO. | DOWNLOAD |
|
|
|
| 2018-0101 |
|
| 2018-0101 |
|